Videos

Farrukh Awan, MD, discusses some of the most important advancements in chronic lymphocytic leukemia (CLL) treatment over the past 10 years.

In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dive into the topic of big data: what it is, how it came about, and why we’re still struggling to leverage it.

Ivy Altomare, MD, provides an overview of her study on the characteristics of clinical trials carried out in community oncology practices within the Flatiron Health network in the US.

Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.

Sandip Patel, MD, discusses the latest updates in the non–small cell lung cancer (NSCLC) treatment landscape.

Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).

At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...

According to results from the phase 3 KRYSTAL-12 trial, adagrasib improved survival and response compared to docetaxel among patients with previously treated KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer.